Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... REDWOOD CITY, Calif. , May 1, 2015  AcelRx ... company focused on the development and commercialization of innovative ... today announced that Timothy E. Morris , chief ... events.  Details of the events are as follows: ... Tuesday, May 5 Location:  The Omni Berkshire Place, ...
(Date:4/30/2015)... MOUNTAIN VIEW, Calif., April 30, 2015 Omnicell, Inc. ... and supply management solutions to healthcare systems, today announced ... GAAP results: Revenue for the first quarter ... 14.2% from the first quarter of 2014, and down ... 2014. First quarter 2015 net income as ...
(Date:4/30/2015)... JOLLA, Calif. , April 30, 2015   ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended March ... U.S. financial markets close. Regulus will ... 7, 2015, at 5:00 pm Eastern Daylight Time to ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... candidate, has been granted orphan drug designation from the ... of pediatric Clostridium difficile infection (CDI).  This ... covers all formulations of fidaxomicin used to treat ...
... 2011 ULURU Inc. (NYSE Amex: ULU), ... a portfolio of wound management and oral care products, today ... 5,000,000 shares of its common stock at a price per ... an institutional investor, resulting in gross proceeds of approximately $500,000. ...
Cached Medicine Technology:Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 2Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 3Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection 4ULURU Inc. to Raise $500,000 in Registered Direct Offering 2
(Date:5/3/2015)... " Bubbly Walrus ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... , The best games to play on smartphones are the ... killing brain cells with a video game that just absorbs ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/2/2015)... May 02, 2015 Vancouver fencing company, QS ... provide valuable advice to prospective clients related to their questions ... to install railings around their decks and patios. While that ... that pop up once the person rolls up their sleeve ... installing a railing in finding a gate that matches it. ...
(Date:5/2/2015)... 02, 2015 “ Peachtree Audio ” ... Tech Report, which features the latest and coolest technology ... and special reporter for NewsWatch, conducted the review and ... equipment. , Music is an important part of ... pampered and given the royal treatment. Peachtree Audio does ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2
... research shows that the occurrence of narcolepsy in China ... most frequent in April. A significant increase in narcolepsy ... but the findings now available in Annals of ... and the Child Neurology Society, report flu vaccination was ...
... as "weight shocks," leading people to add a few extra pounds ... new study. But when it comes to large weight gains, ... they are for women. For men, the risk of a ... women, the risk of a large weight gain was most likely ...
... N.C. About 1 in every 120 babies are born ... is critical, requiring special care early in life. CHD is ... than any other birth defect, but often outcomes can be ... and scientists has published an important paper that recommends strategies ...
... By Jenifer Goodwin HealthDay Reporter , SATURDAY, ... to show symptoms of depression than stay-at-home moms, a new ... any slack and have unrealistic expectations about how easy it ... of depression than their more laid-back counterparts. , , Researchers ...
... imaging probe developed by Massachusetts General Hospital (MGH) investigators ... infection of the heart valves. In their ... publication, the team from the MGH Center for Systems ... -associated endocarditis in a mouse model was revealed by ...
... School of Medicine at UCLA and the University of Texas ... which the body can defend against the effects of Clostridium ... approach for treating an intestinal disease that has become more ... In the U.S., several million ...
Cached Medicine News:Health News:Study finds narcolepsy cases in China peak in early spring 2Health News:Large weight gains most likely for men after divorce, women after marriage 2Health News:Large weight gains most likely for men after divorce, women after marriage 3Health News:Newest screen for newborns will indicate heart problems 2Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 2Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 3Health News:Imaging probe allows noninvasive detection of dangerous heart-valve infection 2Health News:Study identifies new way to treat common hospital-acquired infection 2
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
... Medical Billing system allows a practice ... It is integrated with the EMR, ... system interfaces with electronic clearinghouses for ... a set of reports, it presents ...
... Infinity Amylase EPS single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... InfinityTM Amylase EPS reagent provides a ...
Medicine Products: